^
Association details:
| Biomarker: | ALK positive |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) + Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P45.15-Clinical Outcomes, Long-Term Survival and Toleration With Sequential Therapy of First-Line Crizotinib Followed by Alectinib in ALK+ NSCLC
Published date:
08/18/2021
Excerpt:
Medical records of patients with advanced ALK+ NSCLC treated with sequential therapy of first-line CRZ followed by ALEC (no intermittent systemic therapy was allowed between these two ALK-TKIs) from 4 hospitals in China were collected…. Median PFS during the period of ALEC treatment for overall cohort and CRZ-resistant patients was 15.3 months and 13.4 months respectively....Sequential therapy of first-line CRZ followed by ALEC yielded survival benefits for patients resistant to or intolerant of CRZ.
